Moderna to Present at MIT Lecture Series
March 25 2020 - 08:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that Stéphane Bancel, Chief Executive
Officer will participate in the MIT Laboratory for Financial
Engineering (LFE) and Golub Center for Finance and Policy (GCFP)
Distinguished Lecture Series, “Dealing with Coronavirus: An
Industry Perspective” on Wednesday, April 1 from 4:30-6:00 p.m.
EDT.
To register for the webinar, a link will be available under
“Events and Presentations” in the Investors section of the Moderna
website at investors.modernatx.com.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators. Moderna has 24 mRNA development candidates
in its portfolio across all modalities, with 12 in clinical
studies. Four of these programs are in or preparing for Phase 2
studies and the Company is preparing for its first Phase 3
study.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
(Nasdaq: AZN) and Merck, Inc. (Nasdaq: MRK), as well as the Defense
Advanced Research Projects Agency (DARPA), an agency of the U.S.
Department of Defense; the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) within the
U.S. Department of Health and Human Services (HHS). Moderna has
been named a top biopharmaceutical employer by Science for the past
five years.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200325005069/en/
Media: Colleen Hussey Senior Manager, Corporate Communications
203-470-5620 Colleen.Hussey@modernatx.com
Dan Budwick 1AB 973-271-6085 dan@1abmedia.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024